An observational study in Stroke, sponsored by Centre Hospitalier Régional d'Orléans. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Centre Hospitalier Régional d'Orléans · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 543 studies in Stroke with a site in France — 141 open to participants now, 160 under way, 12 of them phase 3. Stroke · France.
Among the 543 studies in Stroke with a site in France, this one is the 47th largest by planned enrollment of the 173 observational ones that give a count, is one of 30 that started in 2026, is one of 175 observational ones, reaches primary completion later than 95 of the 159 other live ones, and was the 522nd registered.
8,268 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
Browse Stroke studies →141 of the 543 studies in Stroke with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18–80
University Hospital, Bordeaux · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Lille · Sites in France
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
543 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 28 · Phase 3 52 · Phase 4 17
First in 1998; this study’s year is marked. 30 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 151 across 1,969 observational studies indexed under Stroke.
Median enrollment 65 across the 368 interventional studies, 180 across the 173 observational. Of the 331 that completed or were terminated, 30 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 543 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Régional d'Orléans is the lead sponsor of 132 studies on the registry; 32 are open to participants now.
Centre Hospitalier Régional d'Orléans has 9 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
49 of the studies in Stroke with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03998852Phase 3University Hospital, BordeauxIn Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy. | 2027-04-13 |
| NCT06059144Phase 3University Hospital, BordeauxInduced Hypertension in Acute PRogrESsive Perforating Artery Stroke Using Peripheral Dilute noREpinephrine | 2027-08-28 |
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT00759304Centre Hospitalier Universitaire de Saint EtienneEvaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events | 2026-12 |
Add all 49 to your calendar (.ics) → With an account.
Among the 543 studies in Stroke with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, single-center observational study evaluates whether handedness is associated with upper-limb motor recovery after a recent unilateral stroke. Adults admitted to the stroke unit with a confirmed unilateral stroke within 5 days are included if they do not object to participation. Upper-limb impairment is assessed early after stroke and at 6 months using standardized clinical scales. Handedness is determined by self-report, and the Edinburgh Handedness Inventory is administered when feasible. The main hypothesis is that left-handed participants may show better upper-limb motor recovery at 6 months than right-handed participants, potentially due to differences in brain motor network lateralization.
Participants hospitalized in the stroke unit with a confirmed unilateral stroke are recruited consecutively. After eligibility verification and absence of objection, baseline data are collected within 5 days post-stroke. Baseline assessments include the Fugl-Meyer Assessment for the Upper Extremity (FMA-UE), the Shoulder Abduction and Finger Extension (SAFE) score, and the National Institutes of Health Stroke Scale (NIHSS) score (post-acute treatment if thrombolysis or thrombectomy was performed). Handedness is recorded after the motor assessments to maintain assessor blinding regarding group membership; the Edinburgh Handedness Inventory is administered when cognitive status allows. A 6-month follow-up is performed during routine post-stroke consultation at the study site, with repeat FMA-UE and SAFE assessments. The primary analysis compares FMA-UE at 6 months between left-handed and right-handed participants among those with baseline FMA-UE less than 66, using propensity score matching (3:1 right-handed to left-handed) accounting for age, baseline motor deficit, lesion side relative to dominance (dominant vs non-dominant hemisphere), and stroke type (ischemic vs hemorrhagic).
Adults hospitalized in the stroke unit of Orléans University Hospital with a confirmed unilateral recent stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: evaluation
Patients will be evaluated at baseline for Edinburgh Handedness Inventory Laterality Quotient. Patients will be seen again at 6 months as part of their standard post-stroke consultation at Orléans University Hospital by a neurologist from the neurology department. In conjunction with this consultation, an assessment specific to this research study of the FMA-UE and SAFE scores will be carried out by a physiotherapist from the department.
Fugl-Meyer Assessment for Upper Extremity (FMA-UE) Score
Upper-limb motor impairment measured using the Fugl-Meyer Assessment for the Upper Extremity (FMA-UE) at 6 months post-stroke. Scores range from 0 to 66, with higher scores indicating less impairment. Primary analysis is performed among participants with baseline FMA-UE less than 66.
Time frame: month 6
Mean Fugl-Meyer Assessment for Upper Extremity (FMA-UE) Score
Score from 0 to 66; the lower the score, the more severe the deficit
Time frame: Baseline
Proportion of Left-Handed Participants
Time frame: Baseline
Mean National Institutes of Health Stroke Scale (NIHSS) Score
Score from 0 to 42; the higher the score, the more severe the deficit
Time frame: Baseline
Number of Participants With Upper-Limb Weakness
Number of Participants With Upper-Limb Weakness Defined as SAFE Score Less Than 10
Time frame: Baseline
Correlation Between Edinburgh Handedness Inventory Laterality Quotient and Baseline FMA-UE Score
Score from -100 to +100, no notion of severity here since it assesses manual preference (at -100 you are very left-handed and at +100 you are very right-handed)
Time frame: Baseline
Mean Shoulder Abduction and Finger Extension (SAFE) Score
Score from 0 to 10; the lower the score, the more severe the deficit.
Time frame: Month 6
Started Jun 2026 (actual). Primary completion is estimated for Oct 2027, 16 months after the start.
Of 837 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 16 months is below that.
Counting every sponsor, half of 899 studies reached it within 40 months; a quarter within 18 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Régional d'Orléans →